Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
Sign Up to like & getrecommendations! Published in 2023 at "Drug Metabolism and Disposition"
DOI: 10.1124/dmd.122.001096
Abstract: Taselisib (also known as GDC-0032) is a potent and selective phosphoinositide 3-kinase (PI3K) inhibitor that displays greater selectivity for mutant PI3Kα than wild-type PI3Kα. To better understand the absorption, distribution, metabolism, and excretion properties of… read more here.
Keywords: metabolism; taselisib; rats dogs; excretion taselisib ... See more keywords